BOLD Capital Partners

Excited to share this article about Carly's experience using the Feno Smartbrush and visiting our office and lab in LA. Thank you to Carly and CNET for this awesome feature! Check it out here: https://lnkd.in/gcNtsQg6

Sharing a timelapse of a small fleet of Figure 02 humanoid robots doing work Our robots are reasoning fully autonomously Much of the core engineering infrastructure has been laid the last two years, 2025 is going to be 🤯

Breaking Down Barriers in Behavioral Health KeyCare is excited to announce our partnership with Array Behavioral Care, as highlighted in MobiHealthNews! By integrating behavioral and physical health within our Epic-based platform, we're empowering clinicians to: 👉 Connect Seamlessly: Collaborate with broader care teams. 👉 Share Data Real-Time: Gain a comprehensive view of patient health. 👉 Deliver Tailored Care: Provide the right treatment, at the right time. As our CEO, Lyle Berkowitz, MD, FACP, FHIMSS states, "We are not building our own behavioral health group, so to be able to serve as a partner and ensure that patients and our clients have easy access to a really mature behavioral health group was super important to us." Shannon Werb, CEO of Array Behavioral Care emphasizes the value of the partnership, stating, “This collaboration demonstrates the power of technology-enabled care to address fragmentation in the behavioral health space, ensuring patients get the right care at the right time through a unified care experience.” Together with Array, we're redefining the future of healthcare, bridging gaps in care and creating a more connected healthcare experience. Read more about how we are transforming care: https://lnkd.in/dg9b2Gay #behavioralhealth #mentalhealth #healthcareinnovation #digitalhealth #integratedcare #virtualhealthcare

Gameto is #hiring! We are looking to expand our team in both our Austin and NYC locations, spanning commercial and scientific roles. Check out the open roles in Austin: Commercial Operations Manager/Director: https://lnkd.in/eBym8pKV Contract Manager: https://lnkd.in/e247TUcJ Global Compliance and Logistics Specialist: https://lnkd.in/e4Air69y If you are passionate about the women’s health space, a hard working individual, and thrive in a fast-paced, high growth environment, apply to join our team! All applications should be submitted through their respective LinkedIn job postings for consideration.

🌟 Our story, your journey 🌟 At Meru Health, we're not just building a product—we're building connections, creating impact, and striving to make a meaningful difference in the lives of those we serve. We’re thankful to partner with our community to make mental health more accessible, impactful, and human-centered. Watch to see how we’re turning our vision into reality—and join us on this journey. 🚀 https://lnkd.in/gxdnGsWp #OurStory #MentalHealthInnovation #CompanyMission

🔇 Announcing the latest publication from ACS Publications, and the JAMCDD Journal: Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer Abstract: Hematopoietic progenitor kinase 1 (HPK1) has emerged as an attractive target for immunotherapy due to its critical role in T cell activation and proliferation. The major challenge in developing HPK1 inhibitors lies in balancing kinase selectivity, pharmacokinetic (PK) properties, and therapeutic efficacy. In this study, we report a series of pyridine-2-carboxamide analogues demonstrating strong HPK1 inhibitory activity in enzymatic and cellular assays, along with good kinase selectivity. Among these analogues, compound 19 showed good in vitro HPK1 inhibitory activity, excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK), and robust in vivo efficacy in the CT26 (tumor growth inhibition (TGI) = 94.3%, 2/6 CRs) and MC38 murine colorectal cancer models (TGI = 83.3%, 1/6 complete response) when administered in combination with anti-PD-1. Compound 19 also demonstrated adequate in vitro ADME and in vivo PK properties, displaying good oral bioavailability across multiple species (F % = 35–63). These findings summarize our compound’s favorable safety and efficacy profiles, justifying its testing in future translational studies. Check out the full publication here: https://lnkd.in/eZX_sZrV #MedicinalChemistry #Pharmacokinetic #efficacy #cancertreatment

📈Discover the essentials of HIPAA training requirements in our latest blog. Learn what it means, its objectives, requirements, and best practices for successful implementation. 🔍Read Now: https://lnkd.in/gDp63YCw Unlock #HIPAA compliance insights! Book a #Demo with Akitra now at akitra.com/demo #Akitra #Cybersecurity #Blog #HIPAA #Training #Compliance #InformationSecurity #ReadMore #CompliaceSolutions #Compliance #Automation

The FDA’s recent guidance on “Conducting Trials with Decentralized Elements” highlights the transformative power of digital health technologies (DHTs) for at-home data collection, expanding research possibilities and facilitating participant-friendly trials. Whether you’re conducting large-scale global trials or localized studies, we provide a customizable technology solution for cardiac safety, ensuring accurate, real-time monitoring tailored to your decentralized or hybrid trial needs. Learn More: https://lnkd.in/gVzNTtxm #ClinicalTrials #DCTs #Innovation #FDA #Healthcare #ClinicalResearch #Pharma #AliveCor #ECG #CardiacSafety #HealthTech #DigitalHealth

👏 🏆 Congratulations to Alex Zhavoronkov on this incredible achievement from Clarivate!

One of the most common responses to our approach to using genetic technology to address the extinction crisis is that humans shouldn't ""play God."" But as our head of bioethics, Alta Charo, explains—we are part of nature. We are not separate from it. And we have a responsibility to correct the mistakes of our past 🌎 Alta Charo is a Professor Emerita at the University of Wisconsin with over 30 years of expertise in law and bioethics, serving on national and global committees on genome editing and biotechnology 🧬